As of 2026-03-17, the Relative Valuation of Aclaris Therapeutics Inc (ACRS) is (10.32) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.54 USD, the upside of Aclaris Therapeutics Inc based on Relative Valuation is -391.6%.
The range of the Relative Valuation is (9.87) - (11.15) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.5x - 19.2x | 18.0x |
| Forward P/E multiples | 14.7x - 18.6x | 16.4x |
| Fair Price | (9.87) - (11.15) | (10.32) |
| Upside | -378.9% - -414.8% | -391.6% |
| Date | P/E |
| 2026-03-13 | -5.91 |
| 2026-03-12 | -5.86 |
| 2026-03-11 | -6.01 |
| 2026-03-10 | -6.12 |
| 2026-03-09 | -5.66 |
| 2026-03-06 | -5.11 |
| 2026-03-05 | -5.21 |
| 2026-03-04 | -5.17 |
| 2026-03-03 | -5.07 |
| 2026-03-02 | -5.09 |
| 2026-02-27 | -4.79 |
| 2026-02-26 | -5.22 |
| 2026-02-25 | -5.52 |
| 2026-02-24 | -5.61 |
| 2026-02-23 | -5.42 |
| 2026-02-20 | -5.41 |
| 2026-02-19 | -5.39 |
| 2026-02-18 | -5.29 |
| 2026-02-17 | -5.44 |
| 2026-02-13 | -5.32 |
| 2026-02-12 | -5.61 |
| 2026-02-11 | -5.66 |
| 2026-02-10 | -6.09 |
| 2026-02-09 | -6.16 |
| 2026-02-06 | -5.96 |
| 2026-02-05 | -5.66 |
| 2026-02-04 | -5.91 |
| 2026-02-03 | -5.79 |
| 2026-02-02 | -6.02 |
| 2026-01-30 | -5.86 |
| 2026-01-29 | -5.72 |
| 2026-01-28 | -5.86 |
| 2026-01-27 | -6.46 |
| 2026-01-26 | -6.38 |
| 2026-01-23 | -7.51 |
| 2026-01-22 | -7.56 |
| 2026-01-21 | -7.38 |
| 2026-01-20 | -7.39 |
| 2026-01-16 | -4.37 |
| 2026-01-15 | -4.46 |
| 2026-01-14 | -4.57 |
| 2026-01-13 | -4.52 |
| 2026-01-12 | -4.44 |
| 2026-01-09 | -4.41 |
| 2026-01-08 | -4.47 |
| 2026-01-07 | -4.47 |
| 2026-01-06 | -4.42 |
| 2026-01-05 | -4.42 |
| 2026-01-02 | -4.81 |
| 2025-12-31 | -5.02 |